Li Tianshu, Takeoka Shinji
Department of Life Science and Medical Bioscience, Graduate School of Advanced Science and Engineering, Waseda University (TWIns), Tokyo, Japan.
Int J Nanomedicine. 2014 Jun 5;9:2849-61. doi: 10.2147/IJN.S58540. eCollection 2014.
With a small amount of maleimide modification on the liposome surface, enhanced cellular uptake of liposomes and drug-delivery efficiency can be obtained both in vitro and in vivo. Herein, we describe the mechanisms underlying this enhanced cellular uptake. Suppression of the cellular uptake of maleimide-modified liposomes (M-GGLG, composed of 1,5-dihexadecyl N,N-diglutamyl-lysyl-L-glutamate [GGLG]/cholesterol/poly(ethylene glycol) - 1,2-distearoyl-sn-glycero-3-phosphoethanolamine [PEG₅₀₀₀-DSPE]/maleimide [M]-PEG₅₀₀₀-Glu2C18 at a molar ratio of 5:5:0.03:0.03) caused by temperature block and addition of serum was alleviated compared with that of liposomes without maleimide modification (GGLG liposomes, composed of GGLG/cholesterol/PEG₅₀₀₀-DSPE/PEG₅₀₀₀-Glu2C₁₈ at a molar ratio of 5:5:0.03:0.03). When 0.01 nM N-ethylmaleimide was used to pre-block cellular thiols, the cellular uptake of M-GGLG liposomes was decreased to approximately 70% in HeLa, HCC1954, MDA-MB-468, and COS-7 cell lines. Moreover, inhibition of a thiol-related reductase such as protein disulfide isomerase resulted in a 15%-45% inhibition of the cellular uptake of M-GGLG liposomes, whereas GGLG liposomes were not influenced. Further, single and mixed inhibitors of clathrin-mediated endocytosis, caveolae-mediated endocytosis, and macropinocytosis did not efficiently inhibit the cellular uptake of M-GGLG liposomes. Using confocal microscopy, we verified that M-GGLG liposomes were localized partially in lysosomes after inhibition of the mentioned conventional endocytic pathways. Therefore, it was hypothesized that the mechanisms underlying the enhanced cellular uptake of liposomes by maleimide modification was thiol-mediated membrane trafficking, including endocytosis and energy-independent transport.
通过在脂质体表面进行少量马来酰亚胺修饰,可在体外和体内提高脂质体的细胞摄取率和药物递送效率。在此,我们描述了这种增强的细胞摄取背后的机制。与未进行马来酰亚胺修饰的脂质体(GGLG脂质体,由1,5-二十六烷基-N,N-二谷氨酰-赖氨酰-L-谷氨酸[GGLG]/胆固醇/聚乙二醇-1,2-二硬脂酰-sn-甘油-3-磷酸乙醇胺[PEG₅₀₀₀-DSPE]/PEG₅₀₀₀-Glu2C₁₈以5:5:0.03:0.03的摩尔比组成)相比,温度阻断和添加血清对马来酰亚胺修饰的脂质体(M-GGLG,由GGLG/胆固醇/聚乙二醇-1,2-二硬脂酰-sn-甘油-3-磷酸乙醇胺[PEG₅₀₀₀-DSPE]/马来酰亚胺[M]-PEG₅₀₀₀-Glu2C18以5:5:0.03:0.03的摩尔比组成)细胞摄取的抑制作用得到缓解。当使用0.01 nM N-乙基马来酰亚胺预阻断细胞巯基时,在HeLa、HCC1954、MDA-MB-468和COS-7细胞系中,M-GGLG脂质体的细胞摄取率降至约70%。此外,抑制一种与巯基相关的还原酶,如蛋白质二硫键异构酶,会导致M-GGLG脂质体的细胞摄取受到15%-45%的抑制,而GGLG脂质体则不受影响。此外,网格蛋白介导的内吞作用、小窝蛋白介导的内吞作用和巨胞饮作用的单一和混合抑制剂均不能有效抑制M-GGLG脂质体的细胞摄取。使用共聚焦显微镜,我们证实了在抑制上述传统内吞途径后,M-GGLG脂质体部分定位于溶酶体中。因此,据推测,通过马来酰亚胺修饰增强脂质体细胞摄取的机制是巯基介导的膜运输,包括内吞作用和能量非依赖运输。